Zika Breaking News

The Pan American Health Organization (PAHO) recently announced that the entire Region of the Americas has lost its verification of endemic measles transmission elimination due to ongoing outbreaks in several countries.

For example, in early November, Canada lost its measles elimination status.

As of November 24, 2023, Mexico's Ministry of Health reported approximately 5,300 cumulative confirmed measles cases this year, primarily in the northern region, just south of New Mexico and Texas.

This data is comparable to Canada's, indicating that Mexico may also lose its measles-free status.

Meanwhile, the United States, located between Canada and Mexico, has reported around 1,753 measles cases this year, with a few ongoing outbreaks, particularly in northern South Carolina.

The standard recommendation shared among these countries and states is that most people should be fully vaccinated with the MMR vaccine to protect themselves from the easily transmissible virus.

The French health ministry today published an updated Bulletin summarizing the unusually high number of chikungunya virus cases this year.

As of November 20, 2025, there have been 87 locally acquired cases of chikungunya in France: 43 in the Gard and 44 in the Hérault, located along France's Mediterranean coast.

Additionally, France confirmed 1,052 imported cases, with about 72% related to travelers from the department of La Réunion, located in the southwest Indian Ocean.

Seperately, Italy has reported 384 local cases, with the largest cluster located in Carpi, San Prospero, Soliera, Novellara, Cavezzo, Modena, Nonantola, Correggio, Novi di Modena, and Cesenatico.

The reasons behind these outbreaks may be weather-related.

On November 17, 2025, the European CDC reported that, according to data in the scientific literature, the ambient temperature is one of the most important environmental factors influencing the mosquito-borne transmission of the chikungunya virus.

The optimal daily average temperature for chikungunya transmission by Ae. albopictus in temperate zones of the Northern Hemisphere is 24–26 °C.

However, transmission might occur within the temperature range of 12 – 30 °C.

Currently, the U.S. CDC advises travelers to these areas to speak with a healthcare provider about chikungunya vaccination options.

According to the Florida Department of Health (DOH), Arbovirus Surveillance Report, Week 46, travelers from Cuba have been diagnosed with various diseases in 2025.

As of November 15, 2025, the DOH reported 73 travel-related cases of chikungunya have been confirmed in Florida this year, with 62 related to Cuba.

In 2025, 355 cases of dengue fever were reported among individuals who had traveled internationally, with 252 cases among travelers from Cuba.

And one Oropouche case was reported in a traveler from Cuba in November.

According to the U.S. CDC, check the vaccines and medicines list and visit your healthcare provider at least a month before your trip to Cuba in 2025. Various travel vaccines are offered at clinics and pharmacies throughout the United States.

The Global Polio Eradication Initiative (GPEI) today reported vaccine-derived poliovirus type 2 (VDPV2) has been detected in an environmental sewage sample collected in Yorkshire and the Humber, in northern England, home to about 5.6 million people.

As of September 16, 2025, the GPEi confirmed that this is the second VDPV2-positive environmental sample reported in the United Kingdom in 2025.

The GPEI says VDPV2 is a strain related to the weakened live poliovirus contained in the oral polio vaccine. If allowed to circulate in under- or unimmunized populations for long enough, or replicate in an immunodeficient individual, the weakened virus can revert to a form that causes illness and paralysis.

The U.S. CDC's Global Polio Travel Health Notice says that Most people with polio do not feel sick. Some people have only minor symptoms, such as fever, tiredness, nausea, headache, nasal congestion, sore throat, cough, stiffness in the neck and back, and pain in the arms and legs. In rare cases, polio infection causes permanent loss of muscle function.

The CDC did include the UK among the 39 countries identified in this Level 2 travel alert.

As of November 18, 2025, the CDC recommends that before traveling to any destination listed, adults who previously completed the complete, routine polio vaccine series may receive a single, lifetime booster dose of polio vaccine.

In the USA, the IPV vaccine is offered at clinics and travel pharmacies. 

Based on internal Wallgreens pharmacy data, the Respiratory Illness Index map shows minimal influenza reports for the 2025-2026 respiratory season.

Seperately, the U.S. CDC Influenza Surveillance Report: Key Updates for Week 45, ending November 8, 2025, says seasonal influenza activity remains low nationally but is increasing in some areas.

On November 14, 2025, the CC wrote that the percent positivity for influenza and the percentage of emergency department visits for influenza among pediatric age groups increased last week. And the timing of the increasing activity is similar to several past seasons, including the 2024-2025 season.

The best news from the CDC is that no influenza-associated pediatric deaths occurring during the 2025-2026 season have been reported to the CDC.

The CDC recommends that everyone ages 6 months and older get an annual influenza vaccine anytime viruses are circulating. 

From an access perspective, more than 121 million doses of influenza vaccine have been distributed in the United States this season, and are readily available at local pharmacies. 

Marburg virus disease has been detected in the South Ethiopia Region, the first of its kind in the country, following laboratory testing of samples from a cluster of suspected cases of viral haemorrhagic fever.

As of November 14, 2025, the World Health Organization (WHO) has reported a total of 9 cases in the outbreak affecting Jinka town in the South Ethiopia Region.

In the African region, previous Marburg outbreaks and sporadic cases have been reported in Angola, the Democratic Republic of the Congo, Ghana, Kenya, Equatorial Guinea, Rwanda, South Africa, Tanzania, and Uganda.

Marburg's initial outbreak was detected in Germany in 1967.

Marburg is a severe and often fatal illness transmitted to humans from fruit bats and spreads among people through direct contact with the bodily fluids of infected individuals or contaminated materials.

The WHO and national authorities are scaling up the response, including community-wide screening, case isolation, treatment, contact tracing, and public awareness campaigns to curb the spread of the Marburg virus, which belongs to the same family of viruses as Ebola virus disease.

Currently, no approved Marburg vaccines are available.

However, in April 2025, the Albert B. Sabin Vaccine Institute recently launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, based on the cAd3 platform.

Currently, about five other Marburg vaccine candidates are being tested in clinical research.

Updated on November 17, 2025 - Organisations undertaking business in Ebola or Marburg-affected areas should register with the UK Health Security Agency returning workers scheme.

Bavarian Nordic A/S announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025.

On November 14, 2025, the Company stated that its revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness.

Specifically, travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand for rabies and Tickborne encephalitis vaccines, and supported by the gradual launch of the chikungunya vaccine, Vimkunya®.

Vimkunya is available in the USA, Germany, and France . The global launch has continued throughout the third quarter of 2025, where the vaccine also became available in the United Kingdom and Denmark in September. Vimkunya was also launched in Sweden, Norway, Finland, Italy, and Spain in October.

On February 14, 2025, the U.S. Food and Drug Administration approved Vimkunya for injection for individuals 12 years of age and older who are visiting chikungunya endemic areas such as Cuba.

This travel vaccine is commercailly offered at clinics and travel pharmacies in the USA.